You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Malignant Hematology Overview – A 2018 Snapshot

The following graphs provide an overview of performance and quality along the malignant hematology care continuum.

Overall, Ontario’s cancer system as a whole is performing well on malignant hematology care compared with other jurisdictions and time trend data. For highlights of bright spots and opportunities to help focus efforts in improving the quality of care delivery for people with hematologic cancer, see Malignant Hematology in Ontario.

To learn more about the significant investments and advancements made to enhance malignant hematology care in Ontario, see the Special Focus story.

Future editions of the Cancer System Quality Index will include additional malignant hematologic indicators (see Indicators Under Development) to ensure the index is robust and fully represents a high-performing cancer system.

Cancer Burden


Age-standardized incidence rate

To learn more, see Cancer Incidence.

  • Acute lymphoblastic leukemia Not rated1.6 per 100000<br />
  • Acute myeloid leukemia Not rated4.6 per 100000<br />
  • Diffuse large B-cell lymphoma Not rated8.2 per 100000
  • Multiple myeloma Not rated8.8 per 100000

Age-standardized 1-year survival ratio

To learn more, see Cancer Survival.

  • Acute lymphoblastic leukemia Room for improvement74 percent<br />
  • Acute myeloid leukemia Bright spot42 percent<br />
  • Diffuse large B-cell lymphoma Room for improvement71 percent
  • Multiple
    myeloma Bright spot81 percent

Age-standardized 5-year survival ratio

To learn more, see Cancer Survival.

  • Acute lymphoblastic leukemia Bright spot57 percent<br />
  • Acute myeloid leukemia Bright spot20 percent<br />
  • Diffuse large B-cell lymphoma Bright spot58 percent
  • Multiple myeloma Bright spot55 percent

Treatment


Median number of days from diagnosis to start of treatment

To learn more, see Time from Diagnosis to First Treatment

  • Acute lymphoblastic leukemia Bright spot7 days<br />
  • Acute myeloid leukemia Room for improvement7.5 days<br />
  • Diffuse large B-cell lymphoma Room for improvement28 days
  • Multiple myeloma Room for improvement27 days

Median number of days from remission to allogeneic transplant

To learn more, see Access to Hematopoietic Cell Transplant.

  • Acute myeloid leukemia Bright spot69 days

Median number of days from second-line chemotherapy to autologous transplant

To learn more, see Access to Hematopoietic Cell Transplant.

  • Diffuse large B-cell lymphoma Room for improvement92.5 days

Median number of days from first systemic treatment to autologous transplant

To learn more, see Access to Hematopoietic Cell Transplant.

  • Multiple myeloma Room for improvement160 days

End-of-Life Care


Emergency department visits in last 30 days of life

To learn more, see Emergency Department Visits in the Last 30 Days of Life.

  • Acute lymphoblastic leukemia Not rated38 percent<br />
  • Acute myeloid leukemia Not rated61 percent<br />
  • Diffuse large B-cell lymphoma Not rated56 percent
  • Multiple myeloma Not rated58 percent

Transfusions in last 2 weeks of life

To learn more, see Intensive Care Unit (ICU) Admissions and Transfusions in the Last 2 Weeks of Life.

  • Acute lymphoblastic leukemia Not rated60 percent<br />
  • Acute myeloid leukemia Not rated58 percent<br />
  • Diffuse large B-cell lymphoma Not rated19 percent
  • Multiple Myeloma Not rated26 percent

Intensive care unit admissions in last 2 weeks of life

To learn more, see Intensive Care Unit (ICU) Admissions and Transfusions in the Last 2 Weeks of Life.

  • Acute lymphoblastic leukemia Not rated42 percent<br />
  • Acute myeloid leukemia Not rated24 percent<br />
  • Diffuse large B-cell lymphoma Not rated16 percent
  • Multiple myeloma Not rated17 percent

 

Legend
Symbol Indicator rating
Bright spot Bright spots
Room for improvement Room for improvement
Not rated Not rated

Indicators without ratings

For more information on indicator ratings and approach, including indicators without ratings, see Highlights: Cancer System Performance in Ontario, 2020.